Abstract: A TE dual-mode resonator is provided. The TE dual-mode resonator has first and second modes. The resonator includes an enclosure having a cavity with an interior surface. The resonator further includes a dielectric resonator body, having a central portion with a plurality of members extending outwardly from the central portion. The dielectric resonator body is coupled directly to the interior surface.

Abstract: A method for producing a pool of biological samples that is quality assured with respect to the load with microorganisms, using a nucleic acid amplification method, in which a screening pool is tested with a high sensitivity nucleic acid amplification method and can be divided into screening subpools, which are tested with a less sensitive nucleic acid amplification method, where individual samples can be picked out and eliminated, is described.

Abstract: The invention relates to a hemostatic sponge based on collagen and an activator or proactivator of blood coagulation homogeneously distributed therein, which is dried and contains a water content of at least 2%, preferably in the range of 2 to 25%, more preferred 10 to 20%, and a method for producing this sponge.

Abstract: Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.

Abstract: A method for the separation of IgG and IgA from an immunoglobulin-containing starting material is described, whereby the method is characterized in that (i) IgG and optionally IgA are adsorbed to a solid inorganic carrier material, (ii) IgA is isolated from the eluate, optionally after selective desorption, whereas IgG remains on the carrier material, and optionally (iii) IgG is isolated from the adsorbate. Furthermore, an IgA preparation is disclosed which demonstrates a low tendency to form aggregates.

Abstract: A medical prosthesis for use within the body which is formed of radiation treated ultra high molecular weight polyethylene having substantially no detectable free radicals, is described. Preferred prostheses exhibit reduced production of particles from the prosthesis during wear of the prosthesis, and are substantially oxidation resistant. Methods of manufacture of such devices and material used therein are also provided.

Abstract: An eyecup shield for use during ocular examinations. The eyecup shield is formed from a cylindrical member having a proximal end with an opening, a distal end with an opening, and a wall. The wall is substantially rigid and has one or more access ports which are sized to receive a finger.

Abstract: Compounds and pharmaceutical compositions useful as plasminogen activator inhibitor (PAI) antagonists are provided. In particular, methods of antagonizing PAI with substituted and unsubstituted aryl and heteroaryl ethers and thioethers are provided.

Abstract: A photochromic coating composition contains a silicon-containing precondensate derived from a hydrolysable silane containing a polymerizable functional group on a hydrolysis-stable radical, a photochromic dye, a stabilizer, and nanoscale particles. The coating composition, when applied to transparent plastic and glass substrates and cured, gives a coating having high light stability and good scratch resistance.

Abstract: The invention relates to nasal or oral administration of a compound containing inactivated influenza virus antigen and aluminum as adjuvant for the prophylaxis of influenza virus infections. Said vaccine is especially suitable for inducing a mucosal IgA immune response and systemic IgG immune response.

Abstract: Using nonvolatile, releasable, mass-labels, the present invention provides for the synthesis and use of mass-labeled compounds to specifically interact with biomolecular targets. Following binding of the mass-labeled compounds to the target molecule, the unique mass-label can be analyzed using mass spectrometry to identify and characterize the target molecule. In one embodiment of the invention, a mass-labeled oligonucleotide probe is used to identify a specific gene sequence. A myriad of mass-labeled compounds may be produced for use in a wide variety of interactions such as oligonucleotide-oligonucleotide hybridization, polynucleotide-polynucleotide interactions, enzyme-substrate or substrate analog/intermediate interactions, polypeptide-nucleic acid interactions, protein-ligand interactions, receptor-ligand interactions, polypeptide-metal interactions, nucleic acid-metal interactions or antigen-antibody interactions.

Abstract: Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which includes peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.

Abstract: Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.

Abstract: A device to provide body fluid flow control in the form of a valve to be located within a duct or passageway. The device is controlled through pressure above a preselected threshold. Bulk resilience about a passageway in a valve body provides the mechanism for controlled flow. One-way valve operation may be provided through a flap or through a pressure differential on the valve body depending upon the direction of flow. A frame structure positioned within a resilient seal includes longitudinally elongate elements which may be of spring material, malleable material or heat recoverable material so as to accomplish an initial insertion state and an expanded anchoring state. A valve support transitions between the resilient seal portion and the valve body to insure that the states do not change the threshold opening pressure. Insertion devices may be employed to position and actuate a change of state of the frame in the body duct or passageway.

Abstract: The invention concerns HER2-transgenic non-human mammals, animal models for screening drug candidates for the treatment of diseases and disorders associated with the overexpression of HER2. In particular, the invention concerns animal models designed to test drug candidates for the treatment of HER2-overexpressing cancers, including breast cancer, that are not responding or poorly responding to current treatments.

Abstract: Thienyl-, furyl- and pyrrolyl-sulfonamides, formulations of pharmaceutically-acceptable salts thereof and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl)furylsulfonamides and N-(isoxazolyl)pyrrolylsulfonamides, formulations thereof and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit the activity of endothelin are also provided.

Abstract: Novel fusions of a GPI signal domain and a polypeptide heterologous to the GPI signal domain donor polypeptide are provided for industrial use. Therapeutic administration of the GPI-linked product of the fusions enables the targeting of biological activity to cell membrane surfaces.

Abstract: The invention relates to a method for coating a substrate according to which a self-crosslinking coating composition is produced on the basis of a) at least one hydrolysable silane with at least one nonhydrolysable substituent, said silane having one or more electrophilic groups X on at least one nonhydrolysable substitutent, b) at least one hydrolysable silane with at least one nonhydrolysable substituent, said silane having one or more nucleophilic groups Y on at least one nonhydrolysable substituent, c) at least one hydrolysable silane with at least one nonhydrolysable carbonic group that has an average of 2 to 30 fluorine atoms that are bound to one or more aliphatic carbon atoms that are separated from the silicon atom by at least two atoms.

Abstract: A medical instrument includes a needle nozzle that accepts a needle cam. A needle hub assembly includes a needle hub and a needle cannula, and when registration ribs of the needle hub are fitted between respective registration ribs of the needle cam, the needle is thereby fitted onto the medical instrument.

Abstract: Semiconductor materials having a porous texture are modified with a recognition element and produce a photoluminescent response on exposure to electromagnetic radiation. The recognition elements, which can be selected from biomolecular, organic and inorganic moieties, interact with a target analyte to produce a modulated photoluminescent response, as compared with that of semiconductor materials modified with a recognition element only.